Deep Longevity will launch Accrua, a US telehealth platform that anchors prescriptions for GLP-1 agonists, peptides and hormone therapy to a blood-based biological age score rather than symptoms alone, with quarterly re-testing. The underlying model draws on a cohort of roughly 2,600 adults followed for 9.2 years, in which each year of gap between biological and chronological age corresponded to a 15% increase in mortality risk. Predictive validity is not the same as treatment utility, and no outcome data yet show that prescribing guided by the score improves results.
Key Points
- Blood-based aging score to anchor GLP-1 and hormone prescribing
- Each year of age gap linked to 15% higher mortality
- No published evidence that score-guided treatment improves outcomes
Longevity Analysis
Aging clocks move from curiosity to clinical decision-making here, which raises the standard of evidence they must meet. A composite blood score summarizing metabolic, inflammatory and hormonal signals can tell a clinician that something is accelerating, but it cannot specify which system is driving the drift, and quarterly re-testing may track regression to the mean as readily as genuine biological change. The value of such a measure depends on whether it prompts accurate interpretation and sustained behavioral change, rather than serving mainly as a gateway to pharmacotherapy that would have been prescribed anyway.
Original published by Longevity.Technology, by Kyle Umipig.